|Failure rates (first year)|
|Advantages and disadvantages|
|Periods||Depends on the type|
An intrauterine device (IUD), also known as intrauterine contraceptive device (IUCD or ICD) or coil, is a small, often T-shaped birth control device that is inserted into the uterus to prevent pregnancy. IUDs are one form of long-acting reversible birth control (LARC). One study found that female family planning providers choose LARC methods more often (41.7%) than the general public (12.1%). Among birth control methods, IUDs, along with other contraceptive implants, result in the greatest satisfaction among users.
IUDs are safe and effective in adolescents as well as those who have not previously had children. Once an IUD is removed, even after long-term use, fertility returns to normal rapidly. Copper devices have a failure rate of about 0.8% while hormonal (levonorgestrel) devices fail about 0.2% of the time within the first year of use. In comparison, male sterilization and male condoms have a failure rate of about 0.15% and 15%, respectively. Copper IUDs can also be used as emergency contraception within five days of unprotected sex.
Although copper IUDs may increase menstrual bleeding and result in painful cramps, hormonal IUDs may reduce menstrual bleeding or stop menstruation altogether. However, women can have daily spotting for several months and it can take up to three months for there to be a 90% decrease in bleeding with hormonal IUDs. Cramping can be treated with NSAIDs. More serious potential complications include expulsion (2–5%) and rarely perforation of the uterus (less than 0.7%). IUDs do not affect breastfeeding and can be inserted immediately after delivery. They may also be used immediately after an abortion.
The use of IUDs increased within the United States from 0.8% in 1995 to 7.2% from the period of 2006 to 2014. The use of IUDs as a form of birth control dates from the 1800s. A previous model known as the Dalkon shield was associated with an increased risk of pelvic inflammatory disease (PID). However, current models do not affect PID risk in women without sexually transmitted infections during the time of insertion.
IUDs primarily work by preventing fertilization. The progestogen released from hormonal IUDs mainly works by thickening the cervical mucus, preventing sperm from reaching the fallopian tubes. IUDs may also function by preventing ovulation from occurring but this only occurs partially.
Copper IUDs do not contain any hormones, but release copper ions, which are toxic to sperm. They also cause the uterus and fallopian tubes to produce a fluid that contains white blood cells, copper ions, enzymes, and prostaglandins, which is also toxic to sperm. The very high effectiveness of copper-containing IUDs as emergency contraceptives implies they may also act by preventing implantation of the blastocyst.
The types of intrauterine devices available, and the names they go by, differ by location. In the United States, there are two types available:
- Nonhormonal: Copper-containing IUD (ParaGard and others)
- Hormonal: Progestogen-releasing IUD (Mirena and others)
The WHO ATC labels both copper and hormonal devices as IUDs. In the United Kingdom, there are more than 10 different types of copper IUDs available. In the United Kingdom, the term IUD refers only to these copper devices. Hormonal intrauterine contraception is labeled with the term intrauterine system (IUS).
|Hormone (total in device)||None||52 mg
|19.5 mg levonorgestrel|
|Initial amount released||None||20 μg/day||14 μg/day||18.6 μg/day||16 μg/day|
|Approved effectiveness||10 years (12 years)||5 years (10 years)||3 years||3 years (5 years)||5 years|
|Mechanism of action||Copper toxic to sperm||-Levonorgestrel thickens cervical mucus to prevent sperm from reaching egg
-Prevents ovulation at times
|Advantages among IUDs||-No hormones
|-Various hormone level options
-Lighter periods after 3 months; some users experience amenorrhea
|Disadvantages among IUDs||Heavier menstrual flow and cramps||Ovarian cysts (although they can be asymptomatic)|
Most copper IUDs have a T-shaped frame that is wound around with pure electrolytic copper wire and/or has copper collars (sleeves). The arms of the frame hold the IUD in place near the top of the uterus. The Paragard TCu 380a measures 32 mm (1.26") horizontally (top of the T), and 36 mm (1.42") vertically (leg of the T). Copper IUDs have a first year failure rate ranging from 0.1 to 2.2%. They work by damaging sperm and disrupting their motility so that they are not able to join an egg. Specifically, copper acts as a spermicide within the uterus by increasing levels of copper ions, prostaglandins, and white blood cells within the uterine and tubal fluids. The increased copper ions in the cervical mucus inhibit the sperm's motility and viability, preventing sperm from traveling through the cervical mucus, or destroying it as it passes through. Copper can also alter the endometrial lining, and while studies show that while this alteration can prevent implantation of a fertilized egg ("blastocyst"), it cannot disrupt one that has already been implanted.
Advantages of the copper IUD include its ability to provide emergency contraception up to five days after unprotected sex. It is the most effective form of emergency contraception available. It works by preventing fertilization or implantation but does not affect already implanted embryos. It contains no hormones, so it can be used while breastfeeding, and fertility returns quickly after removal. Copper IUDs also last longer and are available in a wider range of sizes and shapes compared to hormonal IUDs. Disadvantages include the possibility of heavier menstrual periods and more painful cramps.
IUDs that contain gold or silver also exist. Other shapes of IUD include the so-called U-shaped IUDs, such as the Load and Multiload, and the frameless IUD that holds several hollow cylindrical minuscule copper beads. It is held in place by a suture (knot) to the fundus of the uterus. It is mainly available in China and Europe. A framed copper IUD called the IUB SCu300 coils when deployed and forms a three-dimensional spherical shape. It is based on a nickel titanium shape memory alloy core. In addition to copper, noble metal, and progestogen IUDs, women in China can get copper IUDs with indomethacin. This non-hormonal compound reduces the severity of menstrual bleeding, and these coils are popular.
Inert IUDs do not have a bioactive component. They are made of inert materials like stainless steel (such as the stainless steel ring (SSR), a flexible ring of steel coils that can deform to be inserted through the cervix) or plastic (such as the Lippes Loop, which can be inserted through the cervix in a cannula and takes a trapezoidal shape within the uterus). They are less effective than copper or hormonal IUDs, with a side effect profile similar to copper IUDs. Their primary mechanism of action is inducing a local foreign body reaction, which makes the uterine environment hostile both to sperm and to implantation of an embryo. They may have higher rates of preventing pregnancy after fertilization, instead of before fertilization, compared to copper or hormonal IUDs.
Inert IUDs are not yet approved for use in the United States, UK, or Canada. In China, where IUDs are the most common form of contraception, copper IUD production replaced inert IUD production in 1993. However, as of 2008, the most common IUD used by immigrants presenting to Canadian clinics for removal of IUDs placed in China was still the SSR. Because the SSR has no string for removal, it can present a challenge to healthcare providers unfamiliar with IUD types not available in their region.
Hormonal IUDs (referred to as intrauterine systems in the UK) work by releasing a small amount of levonorgestrel, a progestin. Each type varies in size, amount of levonorgestrel released, and duration. The primary mechanism of action is making the inside of the uterus uninhabitable for sperm. They can also thin the endometrial lining and potentially impair implantation but this is not their usual function. Because they thin the endometrial lining, they can also reduce or even prevent menstrual bleeding. As a result, they are used to treat menorrhagia (heavy menses), once pathologic causes of menorrhagia (such as uterine polyps) have been ruled out.
Regardless of IUD type, there are some potential side effects that are similar for all IUDs. Some of these side effects include bleeding pattern changes, expulsion, pelvic inflammatory disease (especially in the first 21 days after insertion), and rarely uterine perforation. A small probability of pregnancy remains after IUD insertion, and when it occurs there's a greater risk of ectopic pregnancy.
Menstrual cup companies recommend that women with IUDs who are considering using menstrual cups should consult with their gynecologists before use. There have been rare cases in which women using IUDs dislodged them when removing their menstrual cups, however, this can also happen with tampon use.
Unlike condoms, the IUD does not protect against sexually transmitted infections.
IUDs do not lead to infertility or make it harder for a woman to become pregnant, and fertility typically returns within days of removal. Some prior studies found an association between infertility and the Dalkon Shield, an early form of an IUD which is no longer available for use.
Modern IUDs do not cause increased infection, though the earlier Dalkon Shield may have, because it contained multifilament strings, which provided bacteria a space to grow and move up the string. IUDs manufactured after 2008 use monofilament strings in order to prevent this from happening. However, as with any medical intervention, IUDs can lead to increased risk of infection immediately after the insertion.
According to the U.S. Medical Eligibility Criteria for Contraceptive Use, published by the CDC, women and adolescents under the age of 20 and women who have not given birth are classified in category 2 for IUD use, mainly due due "the risk for expulsion from nulliparity and for STDs from sexual behavior in younger age groups." According to the CDC, benefits generally outweigh the risks, and IUDs are recommended for young and nulliparous women, although more careful attention may be required. Women over age 20 and those who have previously given birth are placed in category 1, meaning no special concerns are placed on use.
Some women experience amenorrhea, or lack of menstruation while using an IUD. Menstruation occurs when a woman has not become pregnant and the uterus sheds its lining in preparation for the next cycle. IUDs tend to thin the lining of the uterus, leading to less menses by volume or a lack of menstruation altogether. There is a condition known as polycystic ovarian syndrome (PCOS) which causes women to miss their periods and can lead to an increased risk of endometrial cancer. However, an IUD causes the endometrial lining of a uterus to thin, which is the opposite of what occurs with PCOS.
The main mechanisms of action of IUDs occur prior to fertilization, by preventing sperm from ever reaching the egg. The copper-bearing IUD acts as a spermicide, killing or impairing sperm so they cannot reach the egg. IUDs that contain progestin cause the cervical mucus to thicken, which stops sperm from entering the uterus.
Insertion and removal
It is difficult to predict what a woman will experience during IUD insertion or removal. Some women describe the insertion as cramps, some as a pinch, and others do not feel anything. Only 9% of nulliparous women considered the procedure painless, 72% moderately painful, and substantial pain with insertion that needs active management occurs in approximately 17% of nulliparous women and approximately 11% of parous women. In such cases, NSAIDs are effective. Topical lidocaine has been found as an effective pain management drug when applied before the procedure.
IUD insertion can occur at multiple timepoints in a woman's reproductive lifespan:
- interval insertion, the most common, occurs remote from pregnancy;
- post-abortion or post-miscarriage insertion occurs following an abortion or miscarriage when the uterus is known to be empty;
- postpartum insertion occurs after a woman gives birth either immediately, while the woman is still in the hospital, or delayed, up to 6-weeks following delivery, following either vaginal delivery or cesarean delivery. Insertion timing changes the risk of IUD expulsion.
During the insertion procedure, health care providers use a speculum to find the cervix (the opening to the uterus), pinch the cervix to stabilize it open with a tenaculum, and then use an insertion device to place the IUD in the uterus. The insertion device goes through the cervix. The procedure itself, if uncomplicated, should take no more than five to ten minutes.
For immediate postpartum insertion, the IUD is inserted following the removal of the placenta from the uterus. The uterus is larger than baseline following birth, which has important implications for insertion. After vaginal deliveries, insertions can be done using placental forceps, a longer inserter specialized for postpartum insertions, or manually, where the provider uses their hand to insert the IUD in the uterus. After cesarean deliveries, the IUD is placed in the uterus with forceps or manually during surgery prior to suturing the uterine incision.
Generally, the removal is uncomplicated and reported to be not as painful as the insertion because there is no instrument that needs to go through the cervix. This process requires the health care provider to find the cervix with a speculum and then use ring forceps, which only go into the vagina, to grasp the IUD strings and then pull the IUD out.
IUD placement and removal can be taught both by manufacturers and other training facilities.
The history of intrauterine devices dates back to the early 1900s. Unlike IUDs, early interuterine devices crossed both the vagina and the uterus, causing a high rate of pelvic inflammatory disease in a time period when gonorrhea was more common. The first IUD was developed in 1909 by the German physician Richard Richter, of Waldenburg. His device was made of silkworm gut and was not widely used.
Ernst Gräfenberg, another German physician (after whom the G-spot is named), created the first Ring IUD, Gräfenberg's ring, made of silver filaments. His work was suppressed during the Nazi regime, when contraception was considered a threat to Aryan women. He moved to the United States, where his colleagues H. Hall and M. Stone took up his work after his death and created the stainless steel Hall-Stone Ring. A Japanese doctor named Tenrei Ota also developed a silver or gold IUD called the Precea or Pressure Ring.
Jack Lippes helped begin the increase of IUD use in the United States in the late 1950s. In this time, thermoplastics, which can bend for insertion and retain their original shape, became the material used for first-generation IUDs. Lippes also devised the addition of the monofilament nylon string, which facilitates IUD removal. His trapezoid shape Lippes Loop IUD became one of the most popular first-generation IUDs. In the following years, many different shaped plastic IUDs were invented and marketed. These included the infamous Dalkon Shield, whose poor design caused bacterial infection and led to thousands of lawsuits. Although the Dalkon shield was removed from the market, it had a lasting, negative impact on IUD use and reputation in the United States. Lazar C. Margulies developed the first plastic IUD using thermoplastics in the 1960s. His innovation allowed insertion of the IUD into the uterus without the need to dilate the cervix.
The invention of the copper IUD in the 1960s brought with it the capital 'T' shaped design used by most modern IUDs. U.S. physician Howard Tatum determined that the 'T' shape would work better with the shape of the uterus, which forms a 'T' when contracted. He predicted this would reduce rates of IUD expulsion. Together, Tatum and Chilean physician Jaime Zipper discovered that copper could be an effective spermicide and developed the first copper IUD, TCu200. Improvements by Tatum led to the creation of the TCu380A (ParaGard), which is currently the preferred copper IUD.
The hormonal IUD was also invented in the 1960s and 1970s; initially the goal was to mitigate the increased menstrual bleeding associated with copper and inert IUDs. The first model, Progestasert, was conceived of by Antonio Scommegna and created by Tapani J. V. Luukkainen, but the device only lasted for one year of use. Progestasert was manufactured until 2001. One commercial hormonal IUD which is currently available, Mirena, was also developed by Luukkainen and released in 1976. The manufacturer of the Mirena, Bayer AG, became the target of multiple lawsuits over allegations that Bayer failed to adequately warn users that the IUD could pierce the uterus and migrate to other parts of the body.
In China, the use of IUDs by state health services was part of the government's efforts to limit birth rates. From 1980 to 2014, 324 million women were inserted with IUDs, in addition to the 107 million who had tubal ligation. Women who refused could lose their government employment and their children could lose access to public schools. The IUDs inserted in this way were modified such that they could not be removed in a doctor's office (meant to be left indefinitely), and surgical removal is usually needed. Until the mid-1990s, the state-preferred IUD was a stainless steel ring, which had a higher rate of complications compared to other types of IUD. It gave rise to the idiom 上环 meaning "insert a loop". Nowadays, the IUDs include T and V shapes, the former being the most common and easiest to remove.
To implement the two-child policy, the government announced that IUD-removals would be paid for by the government. IUD removals are free for women "who are allowed to have another child" (see one-child policy) or "who cannot continue to have the IUD for health reasons."
In the United States, the price of an IUD may range from $0 to $1,300.[clarification needed] The price includes medical exams, insertion, and follow-up visits. Under the Affordable Care Act, most insurance plans are required to cover all forms of birth control, including IUDs, although they may not cover all IUD brands.
- Callahan, Tamara; Caughey, Aaron B. (2013). Blueprints Obstetrics and Gynecology. Lippincott Williams & Wilkins. p. 320. ISBN 9781451117028.
- "ParaGard (copper IUD)". Drugs.com. 7 September 2019. Retrieved 3 December 2019.
- "IUD (intrauterine device)". Contraception guide. NHS Choices. Retrieved 2 March 2014.
the intrauterine device, or IUD (sometimes called a coil)
- Winner, B; Peipert, JF; Zhao, Q; Buckel, C; Madden, T; Allsworth, JE; Secura, GM. (2012). "Effectiveness of Long-Acting Reversible Contraception". New England Journal of Medicine. 366 (21): 1998–2007. doi:10.1056/NEJMoa1110855. PMID 22621627. S2CID 16812353.
- "New Study Finds Women's Health Providers Use IUDs More Than Any Other Method of Birth Control". www.plannedparenthood.org. Retrieved 27 March 2018.
- Committee on Adolescent Health Care Long-Acting Reversible Contraception Working Group, The American College of Obstetricians and, Gynecologists (October 2012). "Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices". Obstetrics and Gynecology. 120 (4): 983–8. doi:10.1097/AOG.0b013e3182723b7d. PMID 22996129. S2CID 35516759.
- Black, K; Lotke, P.; Buhling, K.J.; Zite, N.B.; et al. (Intrauterine contraception for Nulliparous women: Translating Research into Action (INTRA), group) (October 2012). "A review of barriers and myths preventing the more widespread use of intrauterine contraception in nulliparous women". The European Journal of Contraception & Reproductive Health Care. 17 (5): 340–50. doi:10.3109/13625187.2012.700744. PMC 4950459. PMID 22834648.
- Hurd, Tommaso; Falcone, William W., eds. (2007). Clinical reproductive medicine and surgery. Philadelphia: Mosby. p. 409. ISBN 9780323033091.
- Hurt, K. Joseph, ed. (28 March 2012). The Johns Hopkins manual of gynecology and obstetrics (4th ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 232. ISBN 978-1-60547-433-5.
- "Contraception Editorial January 2008: Reducing Unintended Pregnancy in the United States". www.arhp.org. January 2008. Archived from the original on 14 March 2018. Retrieved 14 March 2018.
- "Emergency Contraception - ACOG". www.acog.org. Retrieved 26 March 2018.
- Grimes, D.A. (2007). Hatcher, R.A.; Nelson, T.J.; Guest, F.; Kowal, D. (eds.). "Intrauterine Devices (IUDs)". Contraceptive Technology (19th ed.).
- Gabbe, Steven (2012). Obstetrics: Normal and Problem Pregnancies. Elsevier Health Sciences. p. 527. ISBN 9781455733958.
- Shoupe, Donna (2011). Contraception. John Wiley & Sons. p. 96. ISBN 9781444342635.
- Marnach, ML; Long, ME; Casey, PM (March 2013). "Current issues in contraception". Mayo Clinic Proceedings. 88 (3): 295–9. doi:10.1016/j.mayocp.2013.01.007. PMID 23489454.
- Steenland, MW; Tepper, NK; Curtis, KM; Kapp, N (November 2011). "Intrauterine contraceptive insertion postabortion: a systematic review". Contraception. 84 (5): 447–64. doi:10.1016/j.contraception.2011.03.007. PMID 22018119.
- Roe, Andrea Hsu; Bartz, Deborah (1 January 2019). "Society of Family Planning clinical recommendations: contraception after surgical abortion". Contraception. 99 (1): 2–9. doi:10.1016/j.contraception.2018.08.016. ISSN 0010-7824. PMID 30195718.
- "Products - Data Briefs - Number 188 - February 2015". www.cdc.gov. Retrieved 27 March 2018.
- "Contraceptive Use in the United States". Guttmacher Institute. 4 August 2004. Retrieved 19 April 2019.
- Sonfield, Adam (Fall 2007). "Popularity Disparity: Attitudes About the IUD in Europe and the United States". Guttmacher Policy Review. Guttmacher Institute. Retrieved 4 June 2016.
- Steven G. Gabbe; et al., eds. (1 January 2012). Obstetrics : normal and problem pregnancies (6th ed.). Philadelphia: Elsevier/Saunders. p. 528. ISBN 9781437719352.
- "Understanding the IUD | Center for Research". Archived from the original on 8 August 2013. Retrieved 8 August 2013.
- "Mirena (DIU hormonal) - Mayo Clinic". Mayo Clinic.
- Trussell, James; Schwarz, Eleanor Bimla (2011). "Emergency contraception". In Hatcher, Robert A.; Trussell, James; Nelson, Anita L.; Cates, Willard Jr.; Kowal, Deborah; Policar, Michael S. (eds.). Contraceptive technology (20th revised ed.). New York: Ardent Media. pp. 113–145. ISBN 978-1-59708-004-0. ISSN 0091-9721. OCLC 781956734. p. 121:
Mechanism of action
When used as a regular or emergency method of contraception, copper-releasing IUCs act primarily to prevent fertilization. Emergency insertion of a copper IUC is significantly more effective than the use of ECPs, reducing the risk of pregnancy following unprotected intercourse by more than 99%.2,3 This very high level of effectiveness implies that emergency insertion of a copper IUC must prevent some pregnancies after fertilization.
Emergency contraceptive pills
To make an informed choice, women must know that ECPs—like the birth control pill, patch, ring, shot, and implant,76and even like breastfeeding77—prevent pregnancy primarily by delaying or inhibiting ovulation and inhibiting fertilization, but may at times inhibit implantation of a fertilized egg in the endometrium. However, women should also be informed that the best available evidence indicates that ECPs prevent pregnancy by mechanisms that do not involve interference with post-fertilization events.
ECPs do not cause abortion78 or harm an established pregnancy. Pregnancy begins with implantation according to medical authorities such as the US FDA, the National Institutes of Health79 and the American College of Obstetricians and Gynecologists (ACOG).80
Ulipristal acetate (UPA). One study has demonstrated that UP can delay ovulation.81... Another study found that UPA altered the endometrium, but whether this change would inhibit implantation is unknown.82
Progestin-only emergency contraceptive pills. Early treatment with ECPs containing only the progestin levonorgestrel has been show to impair the ovulatory process and luteal function.83–87
Combined emergency contraceptive pills. Several clinical studies have shown that combined ECPs containing ethinyl estradiol and levonorgestrel can inhibit or delay ovulation.107–110
- RCOG Faculty of Sexual; Reproductive Healthcare; Clinical Effectiveness Unit (January 2012). "Clinical guidance: emergency contraception" (PDF). Clinical Guidance. London: Royal College of Obstetricians and Gynaecologists. ISSN 1755-103X. Retrieved 30 April 2012.p.3:
How does EC work?
In 2002, a judicial review ruled that pregnancy begins at implantation, not fertilisation.8 The possible mechanisms of action should be explained to the patient as some methods may not be acceptable, depending on individual beliefs about the onset of pregnancy and abortion.
Copper-bearing intrauterine device (Cu-IUD). Copper is toxic to the ovum and sperm and thus the copper-bearing intrauterine device (Cu-IUD) is effective immediately after insertion and works primarily by inhibiting fertilisation.9–11 A systematic review on mechanisms of action of IUDs showed that both pre- and postfertilisation effects contribute to efficacy.11If fertilisation has already occurred, it is accepted that there is an anti-implantation effect,12,13
Levonorgestrel (LNG). The precise mode of action of levonorgestrel (LNG) is incompletely understood but it is thought to work primarily by inhibition of ovulation.16,17
Ulipristal acetate (UPA). UPA's primary mechanism of action is thought to be inhibition or delay of ovulation.2
- Treiman K, Liskin L, Kols A, Rinehart W (1995), "IUDs – an update" (PDF), Popul Rep B (6): 1–35, PMID 8724322, archived from the original (PDF) on 20 February 2006, retrieved 1 January 2006
- "Contraceptive coils (IUDs)". NetDoctor.co.uk. 2006. Retrieved 5 July 2006.
- French R, Van Vliet H, Cowan F, et al. (2004). Sorhaindo AM (ed.). "Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy" (PDF). Cochrane Database of Systematic Reviews (3): CD001776. doi:10.1002/14651858.CD001776.pub2. PMC 8407482. PMID 15266453.
- "ParaGard intrauterine copper contraceptive" (PDF). www.paragard.com. Retrieved 14 March 2018.
- "Mirena: Levonorgestrel-releasing intrauterine system" (PDF). www.accessdata.fda.gov. Retrieved 14 March 2018.
- "Syla: levonorgestrel-releasing intrauterine system" (PDF). www.accessdata.fda.gov. Retrieved 14 March 2018.
- "Liletta: levonorgestrel-releasing intrauterine system" (PDF). www.fda.gov. Retrieved 14 March 2018.
- "Kyleena: Levonorgestrel-releasing intrauterine system" (PDF). www.accessdata.fda.gov. Retrieved 14 March 2018.
- Kulier R, O'Brien PA, Helmerhorst FM, Usher-Patel M, D'Arcangues C (2007), "Copper containing, framed intra-uterine devices for contraception", Cochrane Database Syst Rev (4): CD005347, doi:10.1002/14651858.CD005347.PUB3, PMID 17943851
- "Mechanisms of the Contraceptive Action of Hormonal Methods and Intrauterine Devices (IUDs)". Family Health International. 2006. Retrieved 5 July 2006.
- Oritz ME, Croxatto HB (2007). "Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action". Contraception. 75 (6 Suppl): S16–S30. doi:10.1016/j.contraception.2007.01.020. PMID 17531610.
- "Facts are Important: Emergency Contraception (EC) and Intrauterine Devices (IUDs) are Not Abortifacients" (PDF). American Congress of Obstetricians and Gynecologists. 12 June 2014. Retrieved 14 July 2015.
Copper ions released from the IUD create an environment that is toxic to sperm, preventing fertilization.14 Copper can also alter the endometrial lining, but studies show that this alteration can prevent implantation, but not disrupt implantation
- Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J (July 2012), "The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience", Hum. Reprod., 27 (7): 1994–2000, doi:10.1093/humrep/des140, PMC 3619968, PMID 22570193
- Belhadj H, Sivin I, Diaz S, et al. (September 1986), "Recovery of fertility after use of the levonorgestrel 20 mcg/d or Copper T 380 Ag intrauterine device", Contraception, 34 (3): 261–7, doi:10.1016/0010-7824(86)90007-7, PMID 3098498
- Schering (May 13, 2003). "Nova T380 Patient information leaflet (PIL)". Archived from the original on September 28, 2007. Retrieved April 27, 2007.
- Baram I, Weinstein A, Trussell J (February 2014), "The IUB, a newly invented IUD: a brief report", Contraception, 89 (2): 139–141, doi:10.1016/j.contraception.2013.10.017, PMC 3947156, PMID 24309220
- Li Y, Zhang SM, Chen F, et al. (December 2011). "[A multi-center randomized controlled trial of intrauterine device use in Chinese women]". Zhonghua Yi Xue Za Zhi (in Chinese). 91 (45): 3172–5. PMID 22333096.
- Ortiz, ME; Croxatto HB (June 2007). "Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action". Contraception. 75 (6): S16–30. doi:10.1016/j.contraception.2007.01.020. PMID 17531610.
- ESHRE Capri Workshop Group (April 2008). "Intrauterine devices and intrauterine systems". Human Reproduction Update. 14 (3): 197–208. doi:10.1093/humupd/dmn003. PMID 18400840.
- Bilian X (June 2007). "Chinese experience with intrauterine devices". Contraception. 75 (6 Suppl): S31–4. doi:10.1016/j.contraception.2006.12.007. PMID 17531613.
- Cheung VY (June 2010). "A 10-year experience in removing Chinese intrauterine devices". Int J Gynaecol Obstet. 109 (3): 219–22. doi:10.1016/j.ijgo.2009.12.018. PMID 20219193. S2CID 8020802.
- Speroff, Leon; Darney, Philip D. (2011). "Intrauterine contraception". A clinical guide for contraception (5th ed.). Philadelphia: Lippincott Williams & Wilkins. pp. 239–280. ISBN 978-1-60831-610-6. pp. 246–247:
Mechanism of action
The contraceptive action of all IUDs is mainly in the intrauterine cavity. Ovulation is not affected, and the IUD is not an abortifacient.58–60 It is currently believed that the mechanism of action for IUDs is the production of an intrauterine environment that is spermicidal.
Nonmedicated IUDs depend for contraception on the general reaction of the uterus to a foreign body. It is believed that this reaction, a sterile inflammatory response, produces tissue injury of a minor degree but sufficient to be spermicidal. Very few, if any, sperm reach the ovum in the fallopian tube.
The progestin-releasing IUD adds the endometrial action of the progestin to the foreign body reaction. The endometrium becomes decidualized with atrophy of the glands.65 The progestin IUD probably has two mechanisms of action: inhibition of implantation and inhibition of sperm capacitation, penetration, and survival.
- ESHRE Capri Workshop, Group (2008). "Intrauterine devices and intrauterine systems". Human Reproduction Update. 14 (3): 197–208. doi:10.1093/humupd/dmn003. PMID 18400840.
Both copper IUDs and levonorgestrel releasing IUSs may interfere with implantation
- Hatcher, Robert A. (2011). Contraceptive technology (20th rev. ed.). [New York, N.Y.]: Ardent Media. p. 162. ISBN 978-1-59708-004-0.
Although the precise mechanism of action is not known, currently available IUCs work primarily by preventing sperm from fertilizing ova.26 IUCs are not abortifacients: they do not interrupt an implanted pregnancy.27 Pregnancy is prevented by a combination of the "foreign body effect" of the plastic or metal frame and the specific action of the medication (copper or levonorgestrel) that is released. Exposure to a foreign body causes a sterile inflammatory reaction in the intrauterine environment that is toxic to sperm and ova and impairs implantation.28,29 The production of cytotoxic peptides and activation of enzymes lead to inhibition of sperm motility, reduced sperm capacitation and survival, and increased phagocytosis of sperm.30,31… The progestin in the LNg IUC enhances the contraceptive action of the device by thickening cervical mucus, suppressing the endometrium, and impairing sperm function. In addition, ovulation is often impaired as a result of systemic absorption of levonorgestrel
- Luis Bahamondes; M Valeria Bahamondes; Ilza Monteiro. (2008), "Levonorgestrel-releasing intrauterine system: uses and controversies.", Expert Review of Medical Devices, 5 (4): 437–45, doi:10.1586/174344188.8.131.527, PMID 18573044, S2CID 659602
- Malik S (January 2013). "Levonorgestrel-IUS system and endometrial manipulation". Journal of Mid-Life Health. 4 (1): 6–7. doi:10.4103/0976-7800.109625. PMC 3702070. PMID 23833526.
- "ParaGard (copper IUD)". Mayo Clinic. Retrieved 30 November 2018.
- Bahamondes L; Hidalgo M; Petta CA; Diaz J; Espejo-Arce X; Monteiro-Dantas C. (2003), "Enlarged ovarian follicles in users of a levonorgestrel-releasing intrauterine system and contraceptive implant", J. Reproduc. Med., 48 (8): 637–640, PMID 12971147
- "Menstrual Cup use and IUDs". Feminine Wear. Archived from the original on 13 July 2017. Retrieved 22 December 2013.
- "What Are the Side Effects & Complications of the IUD?". www.plannedparenthood.org. Retrieved 21 November 2017.
- Shoupe, Donna; Mishell, Daniel R. Jr. (28 September 2015). The Handbook of Contraception: A Guide for Practical Management. Humana Press. ISBN 9783319201856.
- Gibbs, Ronald S. (2008). Danforth's Obstetrics and Gynecology. Lippincott Williams & Wilkins. ISBN 9780781769372.
- "Classifications for Intrauterine Devices". www.cdc.gov. 9 April 2020. Retrieved 4 August 2022.
- Curtis, Kathryn M.; Tepper, Naomi K.; Jatlaoui, Tara C.; Berry-Bibee, Erin; Horton, Leah G.; Zapata, Lauren B.; Simmons, Katharine B.; Pagano, H. Pamela; Jamieson, Denise J. (2016). "U.S. Medical Eligibility Criteria for Contraceptive Use, 2016". MMWR. Recommendations and Reports. 65 (3): 1–103. doi:10.15585/mmwr.rr6503a1. ISSN 1057-5987. PMID 27467196.
- Dumesic, Daniel A.; Lobo, Rogerio A. (August 2013). "Cancer risk and PCOS". Steroids. 78 (8): 782–785. doi:10.1016/j.steroids.2013.04.004. ISSN 1878-5867. PMID 23624028. S2CID 10185317.
- "Myths and facts about... the Intra-Uterine Device (IUD)". IPPF. 17 February 2012. Retrieved 18 January 2021.
- Marions, Lena; Lövkvist, Lena; Taube, Annika; Johansson, Monica; Dalvik, Håkan; Øverlie, Inger (1 April 2011). "Use of the levonorgestrel releasing-intrauterine system in nulliparous women – a non-interventional study in Sweden". The European Journal of Contraception & Reproductive Health Care. 16 (2): 126–134. doi:10.3109/13625187.2011.558222. ISSN 1362-5187. PMID 21417562. S2CID 43266521.
- Gemzell-Danielsson, K.; Mansour, D.; Fiala, C.; Kaunitz, A. M.; Bahamondes, L. (2013). "Management of pain associated with the insertion of intrauterine contraceptives". Human Reproduction Update. 19 (4): 419–427. doi:10.1093/humupd/dmt022. PMC 3682672. PMID 23670222.
- Karasu, Yetkin; Cömert, Duygu Kavak; Karadağ, Burak; Ergün, Yusuf (June 2017). "Lidocaine for pain control during intrauterine device insertion". The Journal of Obstetrics and Gynaecology Research. 43 (6): 1061–1066. doi:10.1111/jog.13308. ISSN 1447-0756. PMID 28503818. S2CID 4762488.
- "Long-Acting Reversible Contraception: Implants and Intrauterine Devices". www.acog.org. Retrieved 13 April 2020.
- Okusanya, Babasola O; Oduwole, Olabisi; Effa, Emmanuel E (28 July 2014). "Immediate postabortal insertion of intrauterine devices". Cochrane Database of Systematic Reviews (7): CD001777. doi:10.1002/14651858.cd001777.pub4. ISSN 1465-1858. PMC 7079711. PMID 25101364.
- "Early Pregnancy Loss". www.acog.org. Retrieved 13 April 2020.
- Lopez, Laureen M; Bernholc, Alissa; Hubacher, David; Stuart, Gretchen; Van Vliet, Huib AAM (26 June 2015). "Immediate postpartum insertion of intrauterine device for contraception". Cochrane Database of Systematic Reviews (6): CD003036. doi:10.1002/14651858.cd003036.pub3. ISSN 1465-1858. PMID 26115018.
- Jatlaoui, Tara C.; Whiteman, Maura K.; Jeng, Gary; Tepper, Naomi K.; Berry-Bibee, Erin; Jamieson, Denise J.; Marchbanks, Polly A.; Curtis, Kathryn M. (October 2018). "Intrauterine Device Expulsion After Postpartum Placement". Obstetrics & Gynecology. 132 (4): 895–905. doi:10.1097/aog.0000000000002822. ISSN 0029-7844. PMC 6549490. PMID 30204688.
- Johnson, Brett A. (1 January 2005). "Insertion and Removal of Intrauterine Devices". American Family Physician. 71 (1): 95–102. ISSN 0002-838X. PMID 15663031.
- "What's an IUD insertion like?". www.plannedparenthood.org. Retrieved 29 March 2018.
- Whitaker, Amy K.; Chen, Beatrice A. (January 2018). "Society of Family Planning Guidelines: Postplacental insertion of intrauterine devices". Contraception. 97 (1): 2–13. doi:10.1016/j.contraception.2017.09.014. ISSN 0010-7824. PMID 28987293.
- Barnes, Zahra. "This Is What to Expect After Getting Your IUD Removed". SELF. Retrieved 30 March 2018.
- "Clinical Education and Training". www.acog.org. Retrieved 21 August 2019.
- Thiery, Michel (March 1997). "Pioneers of the intrauterine device" (PDF). European Journal of Contraception and Reproductive Health Care. 2 (1): 15–23. doi:10.1080/13625189709049930. PMID 9678105. Archived from the original (PDF) on 20 August 2006.
- Thiery M (June 2000), "Intrauterine contraception: from silver ring to intrauterine contraceptive implant", Eur. J. Obstet. Gynecol. Reprod. Biol., 90 (2): 145–52, doi:10.1016/s0301-2115(00)00262-1, PMID 10825633
- Thiery, M. (March 1997). "Pioneers of the Intrauterine Device" (PDF). The European Journal of Contraception and Reproductive Health Care. 2 (1): 15–23. doi:10.1080/13625189709049930. PMID 9678105. Archived from the original (PDF) on 20 August 2006. Retrieved 24 March 2016.
- Reed, James (1984). The Birth Control Movement and American Society: From Private Vice to Public Virtue. Princeton University Press. p. 306. ISBN 9781400856596.
- Smith (pseudonym), Sydney (8 March 2003). "Contraceptive Concerns". medpundit: Commentary on medical news by a practicing physician. Retrieved 16 July 2006.
- "Legal Current Events | Westlaw Practitioner Insights".
- Wee, Sui-lee (7 January 2017). "After One-Child Policy, Outrage at China's Offer to Remove IUDs". The New York Times. Retrieved 8 January 2017.
- "Chinese ring". www.obgyn.net. 14 July 2011.
- "Intrauterine Devices (IUDs)". www.fhi360.org. Archived from the original on 22 February 2015. Retrieved 22 November 2017.
- "One Child Policy Leaves Millions of Chinese Women With Unwanted IUDs". Radio Free Asia. 13 January 2017.
- "IUD Birth Control | Info About Mirena & ParaGard IUDs". www.plannedparenthood.org. Retrieved 2 December 2018.
- "Where Can I Buy the IUD & How Much Will It Cost?". www.plannedparenthood.org. Retrieved 27 March 2019.